SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose Significant 9.99% Stake in Senti Biosciences

Armistice Capital, LLC and Steven Boyd have jointly disclosed a 9.99% beneficial ownership stake in Senti Biosciences, Inc.'s Class A Common Stock, held for investment purposes.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in Senti Biosciences, Inc.
• The filing pertains to Class A Common Stock, par value $0.0001 per share, of Senti Biosciences, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 536,010 shares of Class A Common Stock.
• This aggregate amount represents 9.99% of the Class A Common Stock outstanding.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Reporting Persons have shared voting power and shared dispositive power over all 536,010 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment by a reputable firm, Armistice Capital, and its managing member, Steven Boyd, in Senti Biosciences, which can be viewed positively as a vote of confidence. The filing is a standard disclosure and does not contain negative operational information about the issuer.

Positives

• Armistice Capital, a recognized investment firm, and its managing member, Steven Boyd, have taken a significant 9.99% stake in Senti Biosciences, which can be interpreted as a vote of confidence in the company's prospects.
• The filing explicitly states that the shares are held for investment purposes in the ordinary course of business, indicating no immediate intent for hostile takeover or control changes.

Future Outlook

NA

Industry Context

NA (This Schedule 13G filing primarily concerns a change in beneficial ownership by an investment firm and does not provide sufficient information to analyze broader industry trends or competitor dynamics.)

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor like Armistice Capital may increase investor confidence and potentially influence market perception positively.

Key Dates

Keywords

Senti Biosciences, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, Class A Common Stock, investment, SEC filing, institutional investor